{
  "pmcid": "11262731",
  "sha256": "0b41c61f6cad8e91ff8c65fcd0f142de5b0305ccb54adac2a0d878df9a9c9793",
  "timestamp_utc": "2025-11-09T23:14:00.260952+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.377811059907835,
    "reading_ease": 27.353978494623675,
    "word_count": 248
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Bleselumab for Prevention of Recurrent Focal Segmental Glomerulosclerosis"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This phase 2a, randomised, open-label trial was conducted at 23 sites in Canada and the United States from May 2017 to May 2021."
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult kidney transplant recipients with biopsy-proven primary FSGS were randomised 1:1."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Randomised 1:1 to receive bleselumab with tacrolimus and corticosteroids or standard of care (SOC) with tacrolimus, mycophenolate mofetil, and corticosteroids."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial assesses bleselumab, an anti-CD40 monoclonal antibody, for preventing recurrent FSGS (rFSGS)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was rFSGS, defined as proteinuria (protein-creatinine ratio ≥3.0 g/g) with death, graft loss, or loss to follow-up imputed as rFSGS, assessed through 3 months posttransplant."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was stratified by previous transplant status."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Of 88 consented patients, 67 were randomised (bleselumab: 33, SOC: 34)."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "63 were analysed (bleselumab: 29, SOC: 34)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Bleselumab showed a 40.7% relative decrease in rFSGS occurrence versus SOC (95% CI, −89.8 to 26.8; P = 0.37)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with infections and gastrointestinal disorders being most common."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov NCT02921789."
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by the sponsor."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}